31 results
6-K
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
to an open label Q2W rademikibart arm (n=86).
An efficacy analysis in patients that achieved Investigator’s Global Assessment scale (“IGA”) 0/1 or Eczema
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
23 Jun 23
House Lease Contract
4:31pm
the relevant formalities for project approval and pass the environmental impact assessment), except for R&D experiments, no hazardous chemicals (including
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
5 Jun 23
Current report (foreign)
4:28pm
involvement; EASI=eczema area and severity Index; IGA=investigator global assessment; LOCF=last observation carried forward; LS=least squares; Q2W=every 2 … -90=at least 50%, 75%, and 90% decreases from baseline; IGA=investigator’s global assessment; LD= loading dose.; PP-NRS=peak pruritus numeric rating
6-K
EX-99.2
i9nvyv1j1oq
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
8gvp1eem48tlux3u7
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
EX-99.1
ecbo5 wne537
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
F-3
EX-1.2
zf9wjz4iubb0 1t3w
15 Apr 22
Shelf registration (foreign)
5:27pm
20-F
4c8szym1 l8te
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-4.13
4c4lzbh97
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-4.12
4jx5fqbvogttgsckgc
31 Mar 22
Annual report (foreign)
4:33pm
6-K
hekf0my177fax fyubv1
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.1
9cmm 87erxjgu5j
5 Jan 22
Current report (foreign)
5:24pm
6-K
EX-99.2
dznm6b1
5 Jan 22
Current report (foreign)
5:24pm
6-K
1ks8dojbyjw0f0
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
6-K
EX-99.1
d4rg a7zg81v
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
6-K
EX-99.2
8ysvo1f615h4zpxd
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am
424B4
s1l x39dmb6
19 Mar 21
Prospectus supplement with pricing info
4:49pm
F-1/A
3zuaqtd pj
18 Mar 21
Registration statement (foreign) (amended)
6:15am